Headquarters: United States
Founded: Recent (2020s)
Ticker: Private
Website: paxostherapeutics.com
Paxos Therapeutics is a biotechnology company focused on developing small molecule therapeutics for Progressive Supranuclear Palsy (PSP) and related 4R-tauopathies. The company's approach targets tau protein aggregation through novel small molecule inhibitors designed to cross the blood-brain barrier and modulate pathological tau species[1].
Paxos represents the growing ecosystem of biotech companies specifically targeting PSP, a disorder that has historically received less commercial attention than Alzheimer's disease or Parkinson's disease but has become increasingly recognized as a pure tauopathy amenable to targeted therapeutic approaches.
Paxos develops small molecule drugs that target the tau aggregation process:
As a pure 4R-tauopathy, PSP presents a specific therapeutic target:
Paxos is in early-stage development with programs targeting tau pathology in PSP:
| Program | Target | Indication | Stage |
|---|---|---|---|
| Small molecule tau inhibitors | Tau aggregation | PSP | Preclinical/Phase 1 |
The company's development strategy follows:
Paxos competes in a crowded but largely unsuccessful space for PSP:
| Company | Drug | Mechanism | Phase |
|---|---|---|---|
| Ferrer | FNP-223 | OGA inhibitor | Phase 2 (PROSPER) |
| Biogen | Gosuranemab | Anti-tau antibody | Phase 2 (failed) |
| AbbVie | Tilavonemab | Anti-tau antibody | Phase 2 (failed) |
| Novartis | NIO752 | Tau ASO | Phase 1 |
| Asceneuron | ASN51 | Tau aggregation | Phase 2 |
| Paxos | TBD | Tau inhibitor | Preclinical |
Paxos's approach is grounded in the understanding that:
4R-Tauopathies - Clinical and therapeutic aspects. Nat Rev Neurol. 2024. ↩︎
Wang Y, et al. Tau aggregation inhibitors for PSP. J Med Chem. 2023. ↩︎